| Features: |
| Cucurbitacin, produced by some plants, especially Cucurbitaceae, as a defense against herbivores. Toxic compound that can form in plants in the gourd family (Zucchini, Squash). Cucurbitacins have been shown to inhibit the growth of various cancer cell lines by interfering with cell cycle progression. Cucurbitacins can affect various signaling pathways involved in cancer progression, such as the NF-κB and STAT3 pathways, which are often dysregulated in cancer. |
| Source: |
| Type: |
| ACLY links energy metabolism provided by catabolic pathways to biosynthesis. ACLY, which has been found to be overexpressed in many cancers, converts citrate into acetyl-CoA and OAA.ATP citrate lyase exhibited upregulation in various tumours. General Tumour Biomarker •ACLY is a key enzyme in cancer metabolism. •ACLY is involved in glucose and lipid metabolism. •Many ACLY inhibitors were developed as anti-cancer agents. ACLY is a key enzyme in cellular metabolism that converts citrate into acetyl‐CoA and oxaloacetate. Acetyl‐CoA is a substrate for lipid synthesis and protein acetylation, processes that are often upregulated in cancer cells to support rapid growth and proliferation. ACLY is found overexpressed in many aggressive cancers. ACLY abundantly consumes citrate from nutrient catabolism (especially glucose and glutamine) to support protein acetylation and intense nucleotide and lipid synthesis. The significant decrease in cytosolic citrate appears to play a central role in cancer metabolism by enhancing the Warburg effect and activating the PI3K / AKT axis promoting ACLY activity in a feedback loop. Thus, the inhibition of factors regulating its expression (such as SREBP1) and its activation (such as AKT) could have an anti-proliferative effect. Elevated ACLY expression has been observed in a number of cancers. In many studies, high levels of ACLY have been associated with more aggressive disease and poorer prognoses. Natural ACLY Inhibitors -Hydroxycitrate (HCA):(widely studied) -EGCG -Quercetin -Resveratrol -Luteolin -Citrate -Cucurbitacin B -Emodin? |
| 1590- | Cuc, | ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism |
| - | Review, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:195 Target#:2 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid